# Rigel Pharmaceuticals Inc. (RIGL) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $48.67, market value $909 million.

## Valuation
- **P/E (trailing): 2.9×** (5-yr avg 9.6×, 3-yr avg 9.6×). Rigel Pharmaceuticals Inc. trades at 2.9× trailing earnings, well below its own five-year average of 9.6×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 9.9×, higher than trailing, so analysts expect earnings to fall.
- **PEG: 0.01**. A PEG of 0.01 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 3.3×**. Each dollar of revenue is priced at 3.3×.
- **Price / book: 2.1×**. The shares trade at 2.1× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 10.3×**. Enterprise value is 10.3× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Earnings yield: 34.7%**. The inverse of the P/E: 34.7% of the price is earned each year.

## Profitability
- **Operating margin: 31.5%**. 31.5% of revenue is left after running the business, an exceptional level.
- **Net margin: 124.7%**. 124.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 93.8%**. A 93.8% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: 17.0%**. Return on all capital, debt included, is 17.0%: comfortably above what that capital costs.
- **Return on assets: 62.7%**. Each dollar of assets produces 62.7% of profit.

## Growth
- **Revenue growth (1 yr): 64.1%** (3-yr 34.8%/yr, 5-yr 22.1%/yr). Revenue grew 64.1% over the last year, against 22.1% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 1867.7%**. Earnings per share rose 1867.7%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.13**. Debt is 0.13 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.1×**. It would take 0.1 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 6.91**. A Z-score of 6.91 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Rigel Pharmaceuticals Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 21.3%** (YTD 13.6%, 3-mo 62.6%). The shares are up 21.3% over twelve months including dividends.
- **From 52-week high: -6.8%** (95.1% above the low). Trading 7% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 67**. An RSI of 67 is neutral.
- **Beta (1 yr): 0.82** (volatility 66%). Beta of 0.82 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=RIGL · Page: https://foliofundamentals.com/stocks/rigl

Not investment advice.